The discovery that tumor vasculature has a molecular profile distinct from normal resting vessels identified tumor vasculature as an important new clinical target. Two recent large studies profiling ...

Reinforces Synergistic Potential and Expands Opportunity Beyond Ovarian Cancer VANCOUVER, BC - January 29, 2026 (NEWMEDIAWIRE ...

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...

Ovarian cancer is a highly lethal gynecological malignancy with limited therapeutic options for recurrent and drug-resistant ...

A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian cancer, highlighting that although most biomarkers show little heterogeneity, ...

The immune system is a major determinant of how patients respond to standard treatments for ovarian cancer, the leading cause of death from gynecological malignancies. But little was known about how ...

A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women facing platinum-resistant ovarian cancer (PROC). Researchers evaluated a novel ...

Some scientists have suspected that the most common form of ovarian cancer may originate in the fallopian tubes, the thin fibrous tunnels that connect the ovaries to the uterus. Now, results of a ...

Scientists at Mount Sinai have unveiled a bold new way to fight metastatic cancer by turning the tumor’s own defenses against ...

In 2026, the spotlight will be on a handful of therapeutic strategies that could change cancer care for patients by offering ...